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c-Cbl, a RING-type ubiquitin E3 ligase, downregulates various receptor tyrosine kinases (e.g., epidermal growth factor
receptor (EGFR)), leading to inhibition of cell proliferation. Moreover, patients with myeloid neoplasm frequently harbor
c-Cblmutations, implicating the role of c-Cbl as a tumor suppressor. Recently, we have shown that c-Cbl downregulates
αPix-mediated cellmigration and invasion, and the lack of c-Cbl in the rat C6 andhumanA172gliomacells is responsible for
their malignant behavior. Here, we showed that c-Cbl exon skipping occurs in the glioma cells and the brain tissues from
glioblastoma patients lacking c-Cbl. This exon skipping resulted in generation of two types of c-Cbl isoforms: type I lacking
exon-9 and type II lackingexon-9 andexon-10.However, the c-Cbl isoforms in the cells and tissues couldnot bedetected as
theywere rapidlydegradedbyproteasome.Consequently,C6andA172cells showedsustainedEGFRactivation.However,
no splice site mutation was found in the region from exon-7 to exon-11 of the c-Cbl gene in C6 cells and a glioblastoma
tissue lacking c-Cbl. In addition, c-Cbl exon skipping could be induced when cells transfected with a c-Cblmini-gene were
grown to high density or under hypoxic stress. These results suggest that unknown alternations (e.g., mutation) of splicing
machinery in C6 and A172 cells and the glioblastoma brain tissues are responsible for the deleterious exon skipping.
Collectively, these findings indicate that the c-Cbl exon skipping contributes to human glioma and its malignant behavior.
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Glioblastoma multiforme (GBM) is the most invasive and aggressive
human brain tumor. Disease-free survival of patients with GBM is
poor even after surgical removal, radiotherapy, and chemotherapy
because of malignant behavior of glioma cells [1,2]. Therefore, unlike
for common types of solid cancer, current experimental therapies for
GBM are mainly focused on inhibition of invasion [3–6]. Numerous
proteins are involved in invasiveness of glioma cells. They include
focal adhesion complex proteins, such as Pix, integrin, and paxillin,
and receptor tyrosine kinases, including epidermal growth factor
receptor (EGFR) and c-Met [7]. Recently, we have shown that the
expression of αPix is dramatically upregulated in the rat C6 and
human A172 glioma cell lines and is critically involved in migration
and invasion of the cells [8].
c-Cbl, a RING type E3 ubiquitin ligase, promotes the degradation of
proteins associated with cell growth andmigration, including EGFR, FAX,
and paxillin [9–13]. Moreover, a wide variety of c-Cbl mutations have
frequently been found in human myeloproliferative diseases, implicatingthe role of c-Cbl as a tumor suppressor. c-Cbl mutations include missense
mutations, frame-shift mutations, insertions, deletion mutations, and
primary transcript splicing mutations [14–20]. Of these, most of deletion
mutations lead to elimination of a part or entire portion of exon-8 or exon-9
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Figure 1. Expression of αPix and c-Cbl in the brain tissues of
patients with GBM. (A) Total mRNAs were isolated from the brain
tissues of normal (N) and GBM patients (P1-P8) by using TRIzol.
They were then subjected to RT-PCR using primers specific to αPix
and c-Cbl. (B) The same brain tissues were homogenized, and their
soluble fractions were subjected to immunoblot with anti-αPix and
anti–c-Cbl antibodies.
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shown that the expression of c-Cbl is dramatically downregulated inC6 and
A172 cells, leading tomarked accumulation ofαPix. Surprisingly, however,
the levels of c-Cbl mRNA in the glioma cells were found to be comparable
to those in normal cells [8]. Therefore, we investigatedwhether c-Cbl in the
glioma cells might be mutated and destabilized.
Here, we showed that deleterious c-Cbl exon skipping occurs in the
brain tissues of GBM patients lacking c-Cbl as well as in C6 and A172
glioma cells. This exon skipping generated two types of c-Cbl isoforms:
type I lacking exon-9 and type II lacking both exon-9 and exon-10.We
further showed that both types of c-Cbl isoforms are inactivated and
destabilized consistent with the fact that exon-9 encodes a part of RING
finger domain essential for the function of c-Cbl as an ubiquitin E3
ligase. The lack of c-Cbl in C6 and A172 cells led to a sustained
activation of epidermal growth factor (EGF) signaling for their increased
cell growth and malignant behavior. However, no splice site mutation
was found in the region from exon-7 to exon-11 of the c-Cbl gene in C6
cells and a GBM brain tissue lacking c-Cbl. Furthermore, c-Cbl exon
skipping could be induced when cells transfected with a c-Cblmini-gene
were grown to high density or under hypoxic stress, suggesting that
alteration in splicing machinery (e.g., mutation) is responsible for c-Cbl
exon skipping. Taken together, our findings indicate that c-Cbl exon
skipping contributes to human glioma and its malignant behavior.
Materials and Methods
Plasmids and Antibodies
cDNAs for c-Cbl and its isoforms were inserted into pFlag-CMV2
or pcDNA-HisMax. A c-Cbl mini-gene construct was generated by
inserting a fragment (6868 bp) of the c-Cbl gene in C6 cells (i.e., the
region from exon-7 to exon-11 including introns) into pFlag-CMV2
and then by fusing green fluorescent protein (GFP) cDNA to the
3′-end of exon-11. All primers were purchased from Bioneer
(Daejeon, Korea).
Antibodies against Flag (Sigma, St Louis, MO), Xpress (Invitrogen,
Grand Island, NY), hemagglutinin (HA) (Roche, Pleasanton, CA),
c-Cbl (Santa Cruz Biotechnology, Dallas, TX), extracellular signal-
related kinase (ERK) (Cell Signaling Technology, Boston, MA), and
phospho-ERK (pERK; Cell Signaling Technology) were used.
Peroxidase-conjugated goat anti-rabbit and anti-mouse IgGs were
purchased from Jackson ImmunoResearch Laboratories (West Grove,
PA). An anti-αPix antibody was generated as previously described [8].
Cell Culture and Hypoxia Induction
Cells were grown at 37°C under an atmosphere of 5% CO2 in
Dulbecco's modified Eagle's medium (Hyclone, Logan, UT) supple-
mented with 1% (vol/vol) antibiotic-antimycotic solution (Welgene,
Gyeongsan, Korea) and 10% (vol/vol) fetal bovine serum (Gibco,
Grand Island, NY). Primary glial cells were prepared from rat brains of
post-natal day 3. Dissociated glial cells were cultured in minimum
essential medium containing 0.6% glucose, 1 mM pyruvate, 2 mM
L-glutamine, 10% horse serum, 100 μg/ml penicillin, and 100 μg/ml
streptomycin. HEK293T and COS7 cells were transfected with
appropriate vectors by using JetPEI (Polyplus, Berkeley, CA), and C6
and A172 cells were done by electroporation (NEON; Invitrogen)
according to the manufacturer’s instructions.
For hypoxia experiments, C6 and A172 cells that had been transfected
with a c-Cbl mini-gene were seeded at a density of ~5 × 105 cells per
100-mm culture dish. They were then exposed for various periods to anambient O2 concentration of 1%, 5%CO2, and 94%N2 at 37°C (using a
controlled incubator with CO2/O2 monitoring and CO2/N2 gas sources).
Immunoprecipitation and Pull-Down Analysis
Cell lysates were prepared in 20 mM Tris-HCl (pH 8.0), 150 mM
NaCl, 0.5% NP-40, and 1× protease inhibitor cocktail (Roche). They
were incubated with appropriate antibodies for 2 hours at 4°C and then
with 30 μl of 50% slurry of protein A-Sepharose (Sigma) for the next 1
hour. The resins were collected by centrifugation, boiled in sodium
dodecyl sulfate–sampling buffer, and subjected to immunoblot analysis.
For pull-down analysis, cell lysates were prepared in Tris-HCl (pH 8.0),
300 mM NaCl, 20 mM imidazole, 0.5% NP-40, and 1× protease
inhibitor cocktail. They were incubated with Ni2+-NTA agarose bead
(NTA; Qiagen, Valencia, CA) for 1 hour at 4°C. The resins were then
collected by centrifugation, boiled in sodium dodecyl sulfate–sampling
buffer, and subjected to immunoblot analysis.
Reverse Transcription–Polymerase Chain Reaction Analysis
The brain tissues of patients with GBM were obtained from the
National Institute of Child Health and Human Development
(NICHD) Brain and Tissue Bank at the University of Maryland
(Baltimore, MD). The identification number for each tissue is given
as follows: UMB# 5117 (normal), 1765 (patient 1: P1), 4538 (P2),
4557 (P3), 1786 (P4), 4517 (P5), 4736 (P6), 4754 (P7), and 5371
(P8). Total mRNAs from cell lines and brain tissues were isolated
using TRIzol (Invitrogen). Reverse transcription–polymerase chain
reaction (RT-PCR) was performed using SuperScript III (Invitrogen)
by following the manufacturer’s instructions. The resulting cDNAs
were then used as templates for PCR amplification. To identify the
skipped c-Cbl exons, the following primers were used:
5′-CTTTACCCGACTCTTTCAGCCCTGGTCCTC-3′ (forward)
and 5′-TTGCTCCCCAGGTGGCAGTTTTGGCACAGG-3′ (re-
verse) for both human and rat c-Cbl. The sequences of primers used
for semiquantitative PCR were 5′-GAACCTATTCAGGCATGG
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Figure 2. c-Cbl exon skipping in glioma cells and the brain tissues of GBM patients. (A) cDNAs for c-Cbl from normal rat cells (NCBI database,
XP_576396), C6 and A172 glioma cells, and the brain tissues of P1 to P3 were subjected to sequence analysis. The primary sequences of
normal c-Cbl (N) and its isoforms (types I and II) were shownwith their functional domains. TKB, PR, and UBA indicate tyrosine kinase-binding
domain, Pro-rich domain, and ubiquitin-associate domain, respectively. The numerals in parentheses indicate the position of amino acids in
c-Cbl from normal human cells (NP_005179.2) and its isoforms from the glioma cells and the tissues of P1 to P3. Note that C6 and A172 cells
were grown to confluence for preparation of c-Cbl cDNA from their total mRNAs. (B) Schematic diagram shows c-Cbl isoforms generated by
two types of exon skipping: type I lacking exon-9 and type II lacking both exon-9 and exon-10. (C) Using the cDNAs as templates, PCR was
performed with primers directed to a region between exon-4/exon-5 and exon-12. The length of PCR product from normal c-Cbl cDNA was
about 1.3 kb. Skipping of exon-9 and both exon-9 and exon-10 led to the generation of PCR products with approximate sizes of 1.1 and 1.0 kb,
respectively. The accession numbers for the sequences of cDNAs for c-Cbl isoforms are KJ944831 (type 1) and KJ944832 (type II) from A172,
KJ944833 (type I) and KJ944834 (type II) from C6, KJ944835 (type I) and KJ944836 (type II) from P1, KJ944837 (type I) and KJ944838 (type II)
from P2, and KJ944839 (type I) and KJ944840 (type II) from P3.
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TAAGTGGAGGTGCAGGTCGTAG-3′ (reverse) for αPix and
5′-ATGGCCGGCAACGTGAAGAAGAGCTCTGGGGCCG-3′
(forward) and 5′-TTCCTTTTAGTTCTGCCAGCATGTGGCT
GAAGAT-3′ (reverse) for c-Cbl.
Thiazoyl Blue Trazolium Bromide Assay
C6 andA172 cells transfectedwith appropriate vectors were seeded at
a density of 1.0 × 104 cells per well and incubated for increasing periods.
Cell proliferation was then determined by incubation with thiazoyl blue
trazolium bromide (MTT; AMERSCO, Solon, OH) for 1 hour. After
incubation, the culture medium was replaced by DMSO to lyse the
cells. Absorbance at 570 nm was then measured by using a Biokinetics
plate reader (Bio-Tek Instruments, Winooski, VT).
DNA Sequencing
Todetermine thenucleotide sequence of genomicDNA(the region from
exon-7 to exon-11 of the c-Cbl gene), total genomic DNAs were prepared
fromC6 cells and the brain tissue of patient P1 (see below). Successive PCRs
were performed along the genomic DNA using appropriate primers to
generate about 500 to 1500 bp, and the products were cloned intopGEM-TEasy (Promega,Madison,WI) vectors. The resulting vectors were
then subjected to sequencing by using Sanger method.
Results
c-Cbl Exon Skipping in C6 and A172 Cells and
Glioma Tissues
We have recently shown that c-Cbl ubiquitinates αPix for
proteasomal degradation and that the rat C6 and human A172
glioma cells lack c-Cbl protein, although they normally express c-Cbl
mRNA [8]. To determine whether the expression patterns of αPix
and c-Cbl are also altered in the brain tissues of patients with GBM,
we first compared the mRNA level of αPix in them (P1-P8). As was
found in C6 and A172 cells [8], the expression of αPix mRNA was
dramatically upregulated in the brain tissues from three patients with
GBM (P1-P3), although not in five other GBM tissues or in a normal
brain tissue (Figure 1A). Consistently, the expression of αPix protein
could be seen only in P1 to P3 (Figure 1B). We then examined
whether the mRNA and protein levels of c-Cbl might also be altered
in the tissues tested. Remarkably, the c-Cbl protein could not be
detected only in P1 to P3 (Figure 1B), despite the finding that c-Cbl
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Figure 3. Exon skipping leads to inactivation and destabilization of c-Cbl. (A) Flag-tagged c-Cbl (N) and its isoforms (ΔE9 and ΔE9/10) were
expressed in HEK293T cells with HisMax-αPix andHA-ubiquitin. After incubationwith 20 μMMG132 for 8 hours, cell lysateswere subjected to
pull-down with NTA resins followed by immunoblot with anti-HA and anti-Xpress antibodies. (B) Flag-tagged c-Cbl and its isoforms were
expressed in C6 cells with HA-ubiquitin. They were then treated as in A. (C) C6 cells expressing Flag-tagged c-Cbl and its isoforms were
incubated with 200 μg/ml cycloheximide in the presence and absence of 20 μMMG132. Cell lysates were then subjected to immunoblot with
anti-Flag antibody. (D) Thec-Cbl bands inCwerescannedusing adensitometer, and their densitieswerequantified by using “ImageJ” software.
The density seen at each “0” time point was expressed as 100% and the others as its relative values. Data are the means ± S.D. (n = 3).
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(Figure 1A). These results indicate that the elevation of αPix protein
level in P1 to P3 is due to the lack of c-Cbl protein, which serves as an
αPix-specific ubiquitin E3 ligase [8]. These findings also raised a possibility
that c-Cbl in the brain tissues of P1 to P3 as well as in C6 and A172 cells
might be mutated and destabilized, resulting in αPix accumulation.
To test this possibility, total mRNAs were prepared from the brain
tissues and the glioma cells and subjected to RT-PCR followed by cDNA
sequencing. Comparison with the known sequences of c-Cbl cDNA
(from the National Center for Biotechnology Information (NCBI)
database) revealed that cDNAs from C6 and A72 cells and the tissues
from P1 to P3 encode two types of c-Cbl isoforms (Figure 2A): type I
lacking the amino acid sequence corresponding to the exact length of
exon-9 and type II lacking that of both exon-9 and exon-10 (Figure 2B).
To show more clearly the exon skipping, PCR was performed using
primers directed to the sequences in the region between exon-4/exon-5
and exon-12. Two types of c-Cbl exon skipping could evidently be seen in
the cDNAs fromC6 and A172 glioma cells (Figure 2C) and the tissues of
P1 to P3 (Figure 2D). These results demonstrate that c-Cbl exon skipping
occurs in bothC6 andA172 glioma cells and the brain tissues of P1 to P3.
Henceforth, the c-Cbl isoforms generated by skipping of exon-9 and both
exon-9 and exon-10 were referred to as ΔE9 and ΔE9/10, respectively.
c-Cbl Isoforms (ΔE9 and ΔE9/10) Are Inactivated
and Destabilized
Skipping of exon-9 leads to elimination of approximately one-half
of the RING domain (see Figure 2A), which is required for the
catalytic function of c-Cbl as an ubiquitin E3 ligase. Thus, it is likely
that both ΔE9 and ΔE9/10 are unable to ubiquitinate αPix. Toconfirm this, the cDNAs for ΔE9 and ΔE9/10 were cloned into
pFlag-CMV vector. Flag-tagged ΔE9 and ΔE9/10 were then
overexpressed in HEK293T cells with αPix and ubiquitin. NTA
pull-down analysis showed that c-Cbl, but not ΔE9 and ΔE9/10,
could ubiquitinate αPix (Figure 3A), indicating that both types of
exon skipping abrogate the ligase function of c-Cbl.
However, neither ΔE9 nor ΔE9/10 could be detected in C6 and
A172 cells and the brain tissues of P1 to P3, suggesting that the c-Cbl
isoforms are unstable, possibly due to the lack of the amino acid
sequence corresponding to exon-9 or both exon-9 and exon-10. To test
this possibility, experiments were performed as in Figure 3A but using
C6 cells and without αPix expression. Unlike normal c-Cbl, both ΔE9
andΔE9/10were heavily ubiquitinated (Figure 3B). Similar results were
obtained when ΔE9 and ΔE9/10 were expressed in A172 cells (Figure
S1). To determine whetherΔE9 andΔE9/10 are indeed degradedmore
rapidly than normal c-Cbl and their degradation is mediated by
proteasome, C6 cells expressing c-Cbl and its isoforms were incubated
with cycloheximide in the presence and absence of MG132, a
proteasome inhibitor. The stability of both ΔE9 and ΔE9/10 was
much lower than that of normal c-Cbl, and their degradation could be
abrogated by treatment with MG132 (Figure 3, C and D). These
results indicate that the lack of c-Cbl proteins in C6 and A172 cells and
the brain tissues of P1 to P3 is due to c-Cbl exon skipping, which results
in rapid proteasomal degradation of both ΔE9 and ΔE9/10.
c-Cbl Exon Skipping Upregulates EGF Signal
c-Cbl is known to play an important role in switching off EGF
signal by downregulating EGFR [17]. Therefore, we examined
whether c-Cbl exon skipping leads to a sustained activation of EGFR.
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even after 2 hours in C6 cells, unlike glial cells, in which EGFR
activation transiently occurred as early as 5 minutes after the
treatment (Figure 4, A and B). Furthermore, ERK phosphorylation
was significantly reduced when C6 cells were complemented with
normal c-Cbl (Figure 4, C and D). However, overexpression of ΔE9
and ΔE9/10 in COS7 cells led to an increase in ERK phosphorylation
(Figure S2), suggesting that the overexpressed ΔE9 and ΔE9/10 could
upregulate EGF signaling by acting dominant negatively to
endogenous c-Cbl. In addition, MTT assay revealed that the
proliferation of C6 cells could significantly be attenuated by the
expression of normal c-Cbl but not by that of its catalytically inactive
mutant (C381A), of which the active site Cys381 is replaced by Ala
(Figure S3). These results suggest that the exon skipping in C6 cells
blocks c-Cbl–mediated down-regulation of EGF signal and, in turn,
promote EGF-mediated cell proliferation and tumorigenesis.
Alteration of Trans-Element(s) Is Responsible for c-Cbl
Exon Skipping
Exon skipping is commonly generated by mutations in splice sites
(cis-elements) or in splicing machinery (trans-elements). To deter-
mine whether any mutation in cis- or trans-element is responsible for
c-Cbl exon skipping, we carried out sequence analysis of the region
from exon-7 to exon-11 of the c-Cbl gene in C6 cells and the brain
tissue of P1. The accession numbers for the genomic DNA sequences
from C6 cells and P1 tissues are KP406160 and KP203813,
respectively. However, no splice site mutation was found in theregion, suggesting that c-Cbl exon skipping is mediated by certain
unknown alteration (e.g., mutation) of trans-elements.
To validate this finding further, we generated a c-Cbl mini-gene by
inserting the genomic DNA fragment (from C6 cells) into
pFlag-CMV followed by fusion of GFP cDNA to the 3′-end of
exon-11 (Figure 5A). Various glioma cell lines were then transfected
with the mini-gene, grown to a high density (2.5 ×107 cells per
100-mm dish), and subjected to RT-PCR by using primers specific to
exon-7 and GFP. Exon skipping of c-Cbl mini-gene could be
observed in C6 and A172 cells, but not in HEK293T, HeLa, or other
glioma cell lines, including U87 and H4 (Figure 5B), indicating that
c-Cbl exon skipping is due to unknown alteration of trans-elements in
C6 and A172 cells, by which the function of splicing machinery
might be constitutively activated or temporally induced under specific
environmental conditions.
To test this possibility, C6 and A172 cells that had been transfected
with c-Cbl-mini gene were grown to high cell density or exposed to
hypoxic stress, both of which are typical environment of cancer cells.
c-Cbl exon skipping, which could not be observed at a density of 5 ×
105 cells per 100-mm dish, was markedly increased upon increasing
the cell density, i.e., at above 5 × 106 cells per dish (Figure 5C).
Exposure to hypoxic stress also induced c-Cbl exon skipping even at a
low cell density, i.e., at 5 × 105 cells per dish (Figure 5D). Unlike in
C6 and A172 cells, however, no c-Cbl exon skipping could be
observed in HeLa and H4 cells under both high cell density and
hypoxic conditions. To determine whether exon skipping indeed
occurs in the primary transcripts of c-Cbl in C6 and A172 cells under
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glioma cells and subjected to RT-PCR. c-Cbl exon skipping, which
could not be seen at a density of 5 × 105 cells, was dramatically
increased upon increasing the density of C6 and A172 cells but not in
HeLa and H4 cells (Figure S4). These results suggest that cell-to-cell
contact and hypoxia somehow influence certain trans-elements to
trigger c-Cbl exon skipping in C6 and A172 cells. These results also
suggest that the glioma cells may overcome contact inhibition and
hypoxia by c-Cbl exon skipping for their survival andmalignant behavior.
Discussion
In the present study, we demonstrated that two types of c-Cbl exon
skipping occur in C6 and A172 glioma cells and the brain tissues of
several GBM patients: type I lacking exon-9 and type II lacking both
exon-9 and exon-10. These exon skipping abrogated the ubiquitin E3
ligase function of c-Cbl, resulting in stabilization of αPix. The
accumulated αPix promoted cell migration and invasion [8], both of
which are typical malignant behavior of cancer cells, such as GBM.
Thus, it appears that c-Cbl exon skipping critically contribute to
human glioma and its malignant behavior.
c-Cbl isoforms generated by exon skipping were found to be much
more unstable than its normal form. However, it is unlikely that the
catalytic activity of c-Cbl is responsible for ubiquitination and
destabilization of itself, because both isoforms lack most part of the
RING domain. It has been reported that c-Cbl can be ubiquitinated
by the HECT-type ubiquitin E3 ligases, such as Itch or Nedd4, for
proteasomal degradation [21]. Thus, it appears possible that Itch orNedd4 may preferentially ubiquitinate the c-Cbl isoforms generated
by exon skipping over the normal c-Cbl ligase.
Human myeloid neoplasms have been shown to be associated with
a variety of c-Cbl mutations, including missense mutations,
frame-shift mutations, insertions, deletion mutations, and primary
transcript splicing mutations. Recently, it has been shown that c-Cbl
mutations also contribute to the pathogenesis of solid tumors [10].
Somatic mutations were found in eight of 119 patients with non–
small cell lung tumors, although only one was inside the linker and
RING-finger regions unlike the mutations that contribute to myeloid
neoplasm that are mostly within the regions. Thus, GBM appears to
represent the second example of c-Cbl–associated solid tumor,
although c-Cbl exon skipping rather than somatic mutations in the
c-Cbl gene itself contributes to GBM. In this respect, it would be
of interest to see if disruption of c-Cbl function may also contribute to
the pathogenesis of other solid tumors.
Of note was the finding that overexpression of c-Cbl isoforms
generated by exon skipping are capable of upregulating EGF
signaling, suggesting that the overexpressed isoforms could act
dominant negatively to endogenous c-Cbl. Cbl-b, a close homolog of
c-Cbl, is thought to also negatively regulate tyrosine kinase signaling,
primarily through its ubiquitin E3 ligase activity [14,22,23].
Significantly, it has been shown that overexpression of c-Cbl mutants
lacking the E3 ligase activity in c-Cbl−/− LKS cells markedly increases
their sensitivity to a broad spectrum of cytokines, including SCF,
TPO, and FLT3 ligand, as compared to that in c-Cbl+/+ cells,
suggesting that the gain-of-function of the c-Cbl mutants may be
524 Deleterious c-Cbl Exon Skipping Seong et al. Neoplasia Vol. 17, No. 6, 2015mediated by their ability to inhibit Cbl-b [24]. Thus, it appears also
possible that the reduction of EGF signaling by c-Cbl isoforms might
be due to inhibition of Cbl-b.
Interestingly, both the type I and type II c-Cbl exon skipping
eliminated the exact length of exon-9 and both exon-9 and exon-10,
respectively. Previously, it has been reported that genomic splice site
mutations (cis-element mutations) cause c-Cbl exon skipping [19,20].
However, no mutation was found in c-Cbl genomic DNA sequence
(at least in the region from exon-7 to exon-11 including introns) from
C6 cells and the brain tissue of P1, suggesting that certain unknown
mutation(s) in trans-elements are responsible for c-Cbl exon skipping.
Moreover, c-Cbl exon skipping could be observed when cells were
grown to high density or under hypoxic conditions. These results
suggest that the environmental factors induce the activation of trans-
elements to catalyze c-Cbl exon skipping. However, how the
environmental factors make the trans-elements exert its splicing
function is not at all known. Neither is known about the nature of
trans-elements involved in c-Cbl exon skipping and what kind of
mutation(s) is present in the trans-elements. Nevertheless, this study
is the first report showing that certain mutation(s) in trans-elements
could acquire a gain-of-function in splicing under certain environmen-
tal conditions, such as high cell density and hypoxic stress. In addition,
c-Cbl exon skipping is clearly different from common alternative
splicing, because only one transcript of c-Cbl has so far been reported in
the transcriptome database unlike alternative splicing, which generates
two or more transcripts from one gene. In this respect, c-Cbl exon
skipping is a new type of splicing, which would require a new term for
future use. For this, we suggest “deleterious exon skipping.”
Appendix A. Supplementary Materials
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.06.003.
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